EPM
DNA icon

Equitec Proprietary Markets’s Ginkgo Bioworks DNA Stock Holding History

Equitec Proprietary Markets’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,200
Closed -$99.4K – 63
2024
Q3 		$99.4K Sell
12,200
-4,612
-27% -$46.2K 0.08% 29
2024
Q2 		$225K Hold
16,812
– – 0.29% 28
2024
Q1 		$780K Sell
16,812
-44,003
-72% -$2.28M 0.48% 24
2023
Q4 		$4.11M Sell
60,815
-2,387
-4% -$146K 3.04% 9
2023
Q3 		$4.58M Sell
63,202
-16,813
-21% -$1.34M 1.13% 15
2023
Q2 		$5.95M Sell
80,015
-11,126
-12% -$659K 1.8% 15
2023
Q1 		$4.85M Sell
91,141
-10,895
-11% -$690K 2.29% 11
2022
Q4 		$6.9M Buy
102,036
+44,879
+79% +$4.13M 2.19% 15
2022
Q3 		$7.13M Sell
57,157
-4,282
-7% -$510K 1.88% 14
2022
Q2 		$5.85M Buy
61,439
+19,878
+48% +$2.42M 1.66% 15
2022
Q1 		$6.7M Buy
41,561
+39,575
+1,993% +$7.7M 1.47% 12
2021
Q4 		$660K Buy
+1,986
New +$943K 0.09% 71

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Equitec Proprietary Markets's DNA Position: Q4 2024 in Review

Equitec Proprietary Markets sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 12,200 shares — an estimated $99.4K sold.

Equitec Proprietary Markets first reported a position in DNA in Q4 2021 and held it in 12 quarters. The position peaked at $7.13M in Q3 2022. 166 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • Equitec Proprietary Markets reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • Equitec Proprietary Markets sold 12,200 Ginkgo Bioworks shares in Q4 2024, an estimated $99.4K.
  • Equitec Proprietary Markets first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 12 quarters.
  • Equitec Proprietary Markets's Ginkgo Bioworks position peaked at $7.13M in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Equitec Proprietary Markets's 13F filing for Q4 2024, filed 29 Jan 2025.